Search
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigational[A7928] Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality … testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigational[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. … [T274] This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
Categories: RAS GTPase InhibitorsSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187547] The drug [MRTX849] is also currently being developed and has the same target.
Categories: RAS GTPase InhibitorsMiltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalThe CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis. … Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent.
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalThis drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830] … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.
Technetium Tc-99m mebrofenin
go.drugbank.com/drugs/DB09137ApprovedWithdrawnLiver and gallbladder imaging is enabled through attachment to mebrofenin as this molecule has high hepatic uptake and fast biliary excretion, resulting in improved hepatic imaging. … This is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray.
Synonyms: Bis(2-[[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetate) technetiumImipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigationalImipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628] … Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.
Oral Malodor (Halitosis)
go.drugbank.com/conditions/DBCOND0035973Drugs: DequaliniumSynonyms: Bad Breath, Bad breath - halitosisUmifenovir
go.drugbank.com/drugs/DB13609Investigational[A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational … [A191475] It has been in use in Russia for approximately 25 years and in China since 2006.